Akebia Therapeutics AKBA
NASDAQ AKBA
$0.92 +0.03 (+3.83%)
At close: Sep 30, 2026 · 4:00 PM EDT

Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2013 - 2026)

Updated

Akebia Therapeutics' Total Non-Current Liabilities was $322.64 million in Q2 2026, up 6.8% from $302.17 million a year earlier but down 3.0% from the prior quarter.

Analysis

Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

At the end of FY2025, Total Non-Current Liabilities at Akebia Therapeutics came in at $340.96 million, up 28.8% from FY2024.

  • Total Non-Current Liabilities shows a five-year compound annual growth rate of 0.1% (FY2020 to FY2025).
  • In earlier years, Total Non-Current Liabilities was $264.66 million in FY2024 (+0.5%), $263.4 million in FY2023 (-21.4%), $335.11 million in FY2022 (-9.7%) and $371.13 million in FY2021 (+9.4%).
  • Quarterly Total Non-Current Liabilities has moved between $245.96 million (Q1 2024) and $436.08 million (Q1 2022) over five years.
  • Compared with a year earlier, Total Non-Current Liabilities has increased for seven straight quarters, with growth averaging 14.0% over the last eight quarters.
  • The best year-over-year quarter for Total Non-Current Liabilities over five years was Q4 2025 (growth of 28.8%); the worst was Q1 2023 (a decline of 35.0%).
  • Per Business Quant data, AKBA's Total Non-Current Liabilities in the three quarters before Q2 2026 was $332.62 million (Q1 2026), $340.96 million (Q4 2025) and $317.32 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 105.99 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 106.45 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 80.25 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -967.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 81.11 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 36.04 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 100.86 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 5.92 Bn
10 Akebia Therapeutics 241.85 Mn -427.63 Mn 38.70 Mn 322.64 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 322.64 Mn
Mar 31, 2026 332.62 Mn
Dec 31, 2025 340.96 Mn
Sep 30, 2025 317.32 Mn
Jun 30, 2025 302.17 Mn
Mar 31, 2025 278.38 Mn
Dec 31, 2024 264.66 Mn
Sep 30, 2024 252.82 Mn
Jun 30, 2024 247.39 Mn
Mar 31, 2024 245.96 Mn
Dec 31, 2023 263.40 Mn
Sep 30, 2023 265.00 Mn
Jun 30, 2023 263.38 Mn
Mar 31, 2023 283.28 Mn
Dec 31, 2022 335.11 Mn
Sep 30, 2022 352.89 Mn
Jun 30, 2022 396.34 Mn
Mar 31, 2022 436.08 Mn
Dec 31, 2021 371.13 Mn
Sep 30, 2021 387.72 Mn
API Access

Akebia Therapeutics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=AKBA&period=max&api_key=YOUR_API_KEY